AlzProtect pens Parexel brain disease pact using new Biotech division

purple brain
The pair will work together on a midstage test for progressive supranuclear palsy. (Raman Oza / Pixabay)

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy (PSP).

The Lille, France-based company will use Parexel for its PSP trial, which is a rare degenerative disease of the brain that causes serious problems with walking, balance and eye movements, using the CRO for work from protocol writing to the coordination of patient recruitment.

It will tap into Parexel’s new “Biotech” unit, a dedicated division launched in January to “support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.”

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology executives

“It was important for us to work with an internationally renowned partner covering the full range of needs for our first phase 2a clinical trial,” said Philippe Verwaerde, president and scientific director of AlzProtect.

“AlzProtect is committed to achieving Phase 2a results in complete confidence. With PAREXEL Biotech, we now have access to the expertise necessary to achieve this goal,” said Laurent Dupire, COO of AlzProtect.

“PAREXEL’S recently launched Biotech unit delivers innovative, customized offerings to the biotech community, building on our more than 20 years of experience in this area,” said Jim Anthony, global head of Biotech, Parexel.  

“Our collaboration with AlzProtect is a great example of how we can work together in a unique way, and we look forward to helping advance this important rare disease initiative.”

Suggested Articles

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.